Clinical trialNCT06297941RecruitingPhase 1Interventional

Study of REM-422 in Patients With AML or Higher Risk MDS

SponsorRemix TherapeuticsEnrollment100Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryHigher Risk Myelodysplastic SyndromesMyelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mythili Koneru, MD
Remix Therapeutics
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France

Centre Hospitalier Universitaire (chu) de Bordeaux
Bordeaux, France
Arnaud Pigneux, MD
Recruiting
Ap-Hp - Hôpital Saint-Louis
Paris, France
Raphael Itzykson, MD
Recruiting
Iuct-Oncopole
Toulouse, France
Pierre Bories, MD
Recruiting
Institut de Cancerologie Gustave-Roussy
Villejuif, France
Stephane De Botton, MD
Recruiting

United States

City of Hope
Duarte, California, United States
Anthony S Stein, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Onyee Chan, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Amir Fathi, MD
Recruiting
Memorial Sloan Kettering
New York, New York, United States
Eytan M Stein, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Courtney D DiNardo, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

REM-422

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Apr 2024
Primary completion: 31 Jul 2027
Completion: 30 Mar 2028
Last update posted: 29 Oct 2026
Registered enrollment: 100
Registry id: NCT06297941

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.